NCT03245801 CAPRI National Juvenile Idiopathic Arthritis Registry
| NCT ID | NCT03245801 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of British Columbia |
| Condition | Juvenile Idiopathic Arthritis (JIA) |
| Study Type | OBSERVATIONAL |
| Enrollment | 1,238 participants |
| Start Date | 2017-02-01 |
| Primary Completion | 2026-02-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 1,238 participants in total. It began in 2017-02-01 with a primary completion date of 2026-02-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Juvenile Idiopathic Arthritis (JIA) is a disorder of unknown cause characterized by chronic inflammation of the joints and other organs. It affects about 1 in a 1000 Canadian children and if untreated it can produce lifelong disability. The Canadian Alliance of Pediatric Rheumatology Investigators (CAPRI) includes most pediatric rheumatologists in Canada. They have successfully collaborated for the past 20 years producing groundbreaking research on the modern course and outcomes of JIA. The CAPRI JIA Registry is an ongoing universal registry of Canadian children with JIA that collects longitudinal data on disease course, outcomes and adverse events to inform healthcare decisions and to gain new insights into the disease and its treatment.
Eligibility Criteria
Inclusion Criteria: 1. All patients newly diagnosed with JIA within the last 3 months 2. All patients who participated in the original ReACCh-Out study 3. LEAP study patients from 'newly diagnosed' and 'ReACCh-Out' cohorts who have completed their two year follow up in LEAP Exclusion Criteria: 1. Patients with an unconfirmed JIA diagnosis 2. Patients diagnosed with JIA more than 3 months prior to the clinic visit, who were not followed in LEAP and /or ReACCh-Out studies. 3. If the family as a whole is unable to answer questionnaires in English or French
Contact & Investigator
Jaime Guzman, MD, FRCPC
STUDY CHAIR
University of British Columbia
Frequently Asked Questions
Who can join the NCT03245801 clinical trial?
This trial is open to participants of all sexes, up to 18 Years, studying Juvenile Idiopathic Arthritis (JIA). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT03245801 currently recruiting?
Yes, NCT03245801 is actively recruiting participants. Contact the research team at jguzman@cw.bc.ca for enrollment information.
Where is the NCT03245801 trial being conducted?
This trial is being conducted at Calgary, Canada, Edmonton, Canada, Vancouver, Canada, Winnipeg, Canada and 11 additional locations.
Who is sponsoring the NCT03245801 clinical trial?
NCT03245801 is sponsored by University of British Columbia. The principal investigator is Jaime Guzman, MD, FRCPC at University of British Columbia. The trial plans to enroll 1,238 participants.